Halozyme Thrp Stock Price, News & Analysis

Halozyme Therapeutics (NASDAQ: HALO) announced FDA approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for treating newly diagnosed light chain (AL) amyloidosis. This marks it as the first FDA-approved treatment for this rare blood disorder, which affects around 4,500 U.S. patients annually. The approval follows positive results from the Phase 3 ANDROMEDA study, where DARZALEX FASPRO® showed a hematologic complete response rate of 42%, significantly higher than the 13% seen with standard treatment (VCd). Continued approval is contingent on further clinical trials.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided its 2021 financial guidance, forecasting revenues between $375 million and $395 million, reflecting a growth of approximately 40% to 45% over 2020. The expected GAAP earnings per share range is $1.40 to $1.55, indicating a 55% to 70% increase compared to the previous year. Key growth drivers include the adoption of subcutaneous DARZALEX^® and Phesgo^®, alongside ongoing collaborations in ENHANZE^® drug development.

Halozyme Therapeutics (NASDAQ: HALO) will have Dr. Helen Torley present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 12:40 p.m. PT. The conference is scheduled from January 11-14, 2021. An audio link to the presentation will be available on Halozyme's website, and a recording will be accessible for 30 days post-event. Halozyme specializes in biopharmaceutical innovations, particularly the ENHANZE® technology, which streamlines drug delivery and enhances patient experiences.

Halozyme Therapeutics has revised its 2020 financial guidance following a global collaboration agreement with Horizon Therapeutics. The company increased its revenue forecast to $265 million to $275 million, up from $250 million to $260 million, indicating a year-over-year growth of 35% to 40%. Earnings per share projections also rose to $0.90 to $0.95, compared to the prior estimate of $0.80 to $0.85. This positive adjustment is attributed to ongoing revenue-generating activities in the fourth quarter.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible on November 25 via the company’s investor relations website. Halozyme focuses on innovative biopharmaceutical solutions, primarily using its proprietary ENHANZE® technology, which enhances drug delivery and has positively impacted over 400,000 patients globally. The company partners with major pharmaceutical firms to develop new therapies, enhancing patient experiences and outcomes.

Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Pharmaceutical submitted applications to both the FDA and EMA for the approval of DARZALEX FASPRO™ subcutaneous formulation. This treatment, aimed at relapsed or refractory multiple myeloma patients, allows administration in 3-5 minutes, vastly reducing the time from the traditional intravenous method. The application is backed by positive results from the Phase 3 APOLLO study suggesting longer progression-free survival compared to the standard treatment. The full study results will be presented at the ASH Annual Meeting on December 6, 2020.

Halozyme Therapeutics (NASDAQ: HALO) has announced that key studies sponsored by Janssen Research & Development will be presented at the American Society of Hematology (ASH) Annual Meeting from December 5-8, 2020. The Phase 3 APOLLO study will feature an oral presentation on December 6 at 3:00 p.m. ET, discussing subcutaneous daratumumab with pomalidomide and dexamethasone in multiple myeloma patients. The ANDROMEDA study results will be presented on December 7, also in an oral format, along with four additional poster presentations.